FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

Peripheral Arterial Disease Clinical Trial

Official title:

A Phase 1, Open Label, Dose Response, Pilot Study to Evaluate the Safety and Tolerability of Human Fibroblast Growth Factor-1 (FGF-1) in Peripheral Arterial Disease Patients With Intermittent Claudication

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT00424866
• Other study ID #: CVBT-2006-PAD-01
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: December 2020
• Est. completion date: June 2022

Study information

• Verified date: October 2019
• Source: CardioVascular BioTherapeutics, Inc.
• Contact: Warren Sherman, MD
• Phone: (972) 681-9368
• Email: wsherman[@]cvbt.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.

Description:

FGF-1 administered by intramuscular injection for the treatment of peripheral arterial disease with intermittent claudication. Eligible patients are allocated to one of three treatment arms. Patients within each dosing group will be randomized between study drug and vehicle control. Safety, pharmacokinetics, and cardiovascular improvement will be evaluated at day 1 and weeks 1, 4 and 12 post dosing.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 24
• Est. completion date: June 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 75 Years

Eligibility

Inclusion Criteria

1. Subjects considered eligible to enter the study must sign an informed consent form prior to the initiation of any study procedures. In the event that the subject must be withdrawn and is re-screened for study participation at a later date, a new informed consent form must be signed. Subjects must be competent to give written informed consent.

2. Age must be =50 and =75 years of age with a life expectancy of > 1 year and leg survival > 6 months. Patients >75 and =80 years of age will be considered if they show no signs of cognitive or muscle function decline and are fully able to comply with the protocol.

3. Patients must have experienced intermittent claudication for at least 6 months and have been stable for the past 3 months.

4. Patients must have peripheral arterial disease, as confirmed by a resting ABI =0.40 and <0.90 based on at least one leg as measured using both the dorsal pedis and posterior tibial arteries.

5. Stenosis of >70% up to total occlusion must be present in the popliteal artery and/or in the tibial peroneal trunk or at least 2 tibial arteries above the ankle without inflow limitation of the popliteal artery. Adequate popliteal inflow is defined as continuous flow from the abdominal aorta, iliac, common femoral and superficial femoral with any stenosis < 50% as determined either by intra-arterial DSA, CTA or Gd CE-MRA.

6. The screening Gardner treadmill test peak walking times (PWT) must be >1 minute and < 12 minutes and limited by pain in one or both calves.

7. Preexisting medication regime must be stable for 6 weeks preceding dosing.

Exclusion Criteria

1. Evidence of critical leg ischemia, i.e. ischemic rest pain or ischemic ulceration

2. Treadmill walking limited by conditions other than intermittent claudication including arthritis, angina and dyspnea

3. Lower limb amputation of, or in, either leg including toes

4. Evidence of limb ischemia from immunologic or inflammatory disorders

5. Leg surgery or revascularization within past 6 months or peripheral angioplasty within past 3 months or anticipated during study

6. Participation in any investigational device or drug trial within the past 6 months

7. Myocardial infarction, unstable angina, stroke or ischemic attack within past 6 months

8. New York Heart Association (NYHA) class II, III or IV heart failure, restrictive or hypertrophic cardiomyopathy or severe valvular disease

9. QTc elongation greater than 450 ms in males or 460 ms in females

10. PT (INR), PTT, urinalysis, thyroid function (T3, T4, TSH) outside normal limits

11. Hemorrhage or thrombotic events (e.g. deep vein thrombosis) within past 6 months

12. Thrombocytopenia (<100,000/µl), history of heparin-induced thrombocytopenia

13. Major surgery with the past 6 months

14. Positive proliferative retinopathy exam

15. Present of any type of cancer or history of cancer except past (but not present) basal cell dermal carcinoma not on either leg

16. Inflammatory or progressive fibrotic or myelofibrotic disorders

17. Patients experiencing bacterial or viral infection (e.g. hepatitis or HIV) or who may otherwise be febrile

18. Hemoglobin A1c(HgbA1c) of >8%

19. Type I diabetes

20. Total fasting cholesterol >200

21. Uncontrolled hypertension (=160 systolic or =100 diastolic pressure) or hypotension (<90 systolic or <60 diastolic pressure)

22. Disease or drug (e.g. systemic corticosteroid) immuno-compromised

23. Hepatic dysfunction as defined either by AST or ALT > 2.0 times the upper limit of normal

24. Serum creatinine of = 2.5 mg/dl

25. Proteinuria (urine protein/creatinine ratio > 3)

26. Antiproliferative drugs (e.g. thalidomide, hydroxyurea)

27. Radiation therapy

28. Implanted devices not compatible with strong magnetic fields

29. Life expectance of less than 1 year

30. Females who are premenopausal and not sterilized or using adequate birth control or are either pregnant, intend to become pregnant or are nursing

Related Conditions & MeSH terms

• Intermittent Claudication
• Peripheral Arterial Disease
• Peripheral Vascular Diseases
• Stenosis

Intervention

Drug:
• FGF-1
Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg Low dose: 3.0 µg/kg Mid dose: 10 µg/kg High dose: 30 µg/kg
• Placebo
Vehicle: 0 µg/kg

Locations

Country	Name	City	State
United States	CVBT Info	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
CardioVascular BioTherapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events as a measure of safety and tolerability of i.m. injected Cardio Vascu Grow TM, a recombinant Human Fibroblast Growth Factor-1 (FGF-1-141)	Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs)	From enrollment through study completion, an average of 12 weeks
Primary	Change from baseline in safety laboratory measurements at 12 weeks	Safety laboratory evaluations on hematology, serum chemistry, and urinalysis	From enrollment through study completion, an average of 12 weeks
Secondary	Plasma FGF-1 (1-141) pharmacokinetic measurements at pre-dose, 5, 15, and 30 minutes and at 1, 2, 4, 6, 10, and 24 hours	Pharmacokinetic plasma concentrations of FGF-1 (1-141)	From enrollment through study completion, an average of 12 weeks